McKesson Corporation (MCK) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
McKesson Corporation (MCK) trades at $853.71 with AI Score 90/100 (Grade A+). McKesson Corporation is a leading healthcare services company, distributing pharmaceuticals and providing healthcare solutions globally. The company operates through four segments: U. S. Market cap: $100.0B, Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: May 10, 2026MCK stock analysis for 2026: Analysts have set a consensus price target of $986.00 for McKesson Corporation, suggesting 15.5% upside from the current price of $853.71. The AI MoonshotScore is 90/100, indicating a strong bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MCK: 2/3 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
McKesson Corporation (MCK) Healthcare & Pipeline Overview
McKesson Corporation, a global healthcare services leader, distributes pharmaceuticals and provides medical solutions. Operating through four segments, including U.S. Pharmaceutical and Medical-Surgical Solutions, McKesson connects pharmacies, providers, payers, and biopharma companies. With a $100.0B market cap, McKesson serves a critical role in healthcare supply chains.
What Is the Investment Thesis for MCK?
McKesson Corporation presents a compelling investment case based on its central role in the healthcare supply chain and its diversified business segments. With a market capitalization of $100.0B and a P/E ratio of 19.6, McKesson demonstrates financial stability. The company's consistent performance is underpinned by its U.S. Pharmaceutical segment, which benefits from the steady demand for pharmaceutical products. Growth catalysts include the expansion of its RxTS segment, focusing on medication adherence solutions, and strategic acquisitions to enhance its international presence. However, investors may want to evaluate potential risks such as regulatory changes in the healthcare industry and competitive pressures from other distributors. The company's low beta of 0.42 suggests lower volatility compared to the market, making it a noteworthy option for risk-averse investors seeking stable returns. McKesson's dividend yield of 0.43% provides a modest income component to the investment.
Based on FMP financials and quantitative analysis
MCK Key Highlights
Market Cap of $100.0B reflects McKesson's significant presence in the healthcare distribution market.
- P/E Ratio of 19.6 indicates a reasonable valuation relative to its earnings.
- Gross Margin of 3.6% demonstrates efficiency in managing the cost of goods sold.
- Dividend Yield of 0.43% provides a modest income stream for investors.
- Beta of 0.42 suggests lower volatility compared to the broader market, indicating a relatively stable investment.
Who Are MCK's Competitors?
MCK is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| SNY Sanofi | $45.44 | -0.85% | $109B | 58 |
| VRTX Vertex Pharmaceuticals Incorporated | $552.06 | +4.52% | $140B | 98 |
| CVS CVS Health Corporation | $93.65 | -1.33% | $119B | 70 |
| GSK GSK plc | $52.88 | +3.38% | $106B | 61 |
| COR Cencora, Inc. | $316.79 | -0.10% | $61.6B | 80 |
| CAH Cardinal Health, Inc. | $231.00 | -1.64% | $54.1B | 90 |
| ABC AmerisourceBergen Corporation | $179.98 | -0.23% | $36.2B | 45 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCK's Key Strengths?
Extensive distribution network and supply chain infrastructure.
- Diversified business segments across pharmaceutical and medical-surgical solutions.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Established market position and brand recognition.
What Are MCK's Weaknesses?
Relatively low profit margin compared to some competitors (1.2%).
- Exposure to regulatory changes and pricing pressures in the healthcare industry.
- Dependence on key suppliers and customers.
- Potential for supply chain disruptions.
What Could Drive MCK Stock Higher?
MCK catalyst: Expansion of the RxTS segment, focusing on medication adherence solutions, is expected to drive revenue growth.
- Potential acquisitions in international markets to expand McKesson's geographic footprint.
- Increased demand for specialty pharmaceuticals and biosimilars is expected to boost sales.
- Leveraging data analytics to improve healthcare outcomes and drive efficiency.
- Development and launch of new technology solutions for healthcare providers.
What Are the Key Risks for MCK?
Regulatory changes in the healthcare industry could impact pricing and reimbursement.
- Intense competition from other pharmaceutical distributors and healthcare providers.
- Cybersecurity threats and data breaches could disrupt operations and damage reputation.
- Pricing pressures from payers and government regulations.
- Product recalls and liability claims.
What Are the Growth Opportunities for MCK?
- Expansion of Prescription Technology Solutions (RxTS): McKesson's RxTS segment offers significant growth potential by addressing medication adherence challenges. The market for medication adherence solutions is expanding as healthcare providers and payers seek to improve patient outcomes and reduce costs. By leveraging technology to connect pharmacies, providers, and biopharma companies, McKesson can capture a larger share of this market. This expansion aligns with the broader trend of digital health solutions and personalized medicine, offering a competitive advantage.
- Strategic Acquisitions in International Markets: McKesson can drive growth through strategic acquisitions in international markets, particularly in Europe and Canada. Expanding its presence in these regions allows McKesson to tap into new customer bases and diversify its revenue streams. These acquisitions can also provide access to new technologies and service offerings, enhancing McKesson's overall competitiveness. The timeline for these acquisitions depends on market conditions and regulatory approvals, but the long-term potential is substantial.
- Increased Focus on Specialty Pharmaceuticals: The specialty pharmaceutical market is growing rapidly, driven by the development of innovative therapies for complex diseases. McKesson can capitalize on this trend by expanding its distribution and support services for specialty pharmaceuticals. This includes providing specialized handling, storage, and logistics services, as well as offering patient support programs. By becoming a preferred partner for specialty pharmaceutical manufacturers, McKesson can secure a significant share of this high-growth market.
- Enhancement of Medical-Surgical Solutions: McKesson's Medical-Surgical Solutions segment can be enhanced by expanding its product offerings and improving its logistics capabilities. This includes offering a wider range of medical supplies and equipment, as well as implementing advanced supply chain management technologies. By providing healthcare providers with a comprehensive suite of products and services, McKesson can strengthen its relationships and increase its market share. The timeline for these enhancements is ongoing, with continuous investments in technology and infrastructure.
- Leveraging Data Analytics for Improved Healthcare Outcomes: McKesson can leverage its extensive data assets to improve healthcare outcomes and drive efficiency. By analyzing data on medication usage, patient demographics, and healthcare costs, McKesson can identify opportunities to optimize treatment plans, reduce waste, and improve patient adherence. This data-driven approach can also help healthcare providers make more informed decisions and improve the quality of care. The implementation of advanced data analytics capabilities is an ongoing process, with continuous investments in technology and expertise.
What Are MCK's Competitive Advantages?
- Extensive distribution network provides a significant logistical advantage.
- Strong relationships with pharmaceutical manufacturers and healthcare providers.
- Comprehensive suite of services creates a sticky customer base.
- Scale and scope provide cost advantages and economies of scale.
What Does MCK Do?
Founded in 1833 and headquartered in Irving, Texas, McKesson Corporation has evolved into a global healthcare services giant. Initially a drug store, the company expanded its operations to include pharmaceutical distribution and healthcare solutions. McKesson operates through four key segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes a wide array of pharmaceutical products, including branded, generic, and specialty drugs, while also offering technology and business solutions to specialty practices and pharmacies. The International segment extends McKesson's reach to wholesale, institutional, and retail customers across 13 European countries and Canada. The Medical-Surgical Solutions segment focuses on providing medical-surgical supply distribution and logistics services to healthcare providers. Lastly, the RxTS segment connects pharmacies, providers, payers, and biopharma companies, delivering innovative access and adherence solutions. McKesson's comprehensive suite of services and extensive distribution network positions it as a critical player in the healthcare ecosystem, facilitating the efficient delivery of pharmaceuticals and healthcare solutions to patients worldwide.
What Products and Services Does MCK Offer?
- Distributes branded, generic, and specialty pharmaceutical drugs.
- Provides medical-surgical supply distribution and logistics services.
- Offers practice management, technology, and clinical support solutions to healthcare providers.
- Connects pharmacies, providers, payers, and biopharma companies.
- Delivers innovative access and adherence solutions for patients.
- Provides consulting, outsourcing, and technological services to pharmacies.
- Offers third-party logistics and wholesale distribution support solutions.
How Does MCK Make Money?
- Distribution of pharmaceutical products to pharmacies and healthcare providers.
- Provision of medical-surgical supplies and equipment.
- Offering technology and business solutions to healthcare practices.
- Generating revenue through service fees and product sales.
What Industry Does MCK Operate In?
McKesson Corporation operates within the medical distribution industry, a critical component of the broader healthcare sector. The industry is characterized by increasing demand for pharmaceuticals and medical supplies, driven by an aging population and advancements in medical treatments. McKesson competes with companies like CVS Health Corporation (CVS) and Bristol-Myers Squibb Company (BMY). The market is also influenced by regulatory changes, pricing pressures, and the increasing importance of supply chain efficiency. The global healthcare market is projected to continue growing, presenting opportunities for McKesson to expand its market share and service offerings.
Who Are MCK's Key Customers?
- Pharmacies (retail and specialty)
- Hospitals and health systems
- Physician practices and clinics
- Biopharmaceutical companies
- Long-term care facilities
McKesson Corporation Financial Trajectory
McKesson Corporation (MCK) reported $105.38B in revenue for Q2 2026, reflecting 9.4% growth compared to the prior quarter. The company recorded net income of $614.0M, with diluted EPS of $5.15. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, MCK averaged $9.34 in diluted EPS.
Company Profile
McKesson Corporation operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Irving, US. The company is led by CEO Brian S. Tyler. MCK has traded publicly since 1994.
How McKesson Corporation Is Valued
McKesson Corporation carries a market capitalization of $100.0B, placing it in the large-cap category. Relative to its peer group, MCK's quantitative score of 90/100 is above the peer average of 75/100.
Key Financial Metrics
Return on assets is 5.8%, showing how much profit it generates from its asset base. MCK trades at a trailing price-to-earnings ratio of 19.57, below the Healthcare sector average of ~23x. Its free cash flow yield is 6.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.85 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 5.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
McKesson Corporation's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 5.82 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
McKesson Corporation has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 2.1% above estimates on average.
Forward Outlook
Wall Street analysts project McKesson Corporation revenue of about $408.47B for fiscal 2026, with EPS near $39.01. The estimate reflects 13 contributing analysts.
MCK Financials
MCK earnings history & estimates →
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in McKesson's future performance, indicating that executives believe the stock is undervalued.
- Community sentiment has shifted positively, with many discussions highlighting the company's strong position in the healthcare supply chain.
- Analysts have noted McKesson's strategic partnerships, which enhance its market reach and operational efficiency.
- The ongoing demand for healthcare services positions McKesson well, as it continues to benefit from increased pharmaceutical distribution needs.
Bear Case
- Concerns about regulatory pressures in the healthcare sector have surfaced, potentially impacting McKesson's operations in the long term.
- Some community members express skepticism about the sustainability of McKesson's recent growth, citing competitive pressures from other healthcare providers.
- Recent headlines regarding supply chain disruptions have raised doubts about McKesson's ability to maintain its service levels.
- Investor sentiment is cautious, with discussions highlighting potential risks associated with economic downturns affecting healthcare spending.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
From the Earnings Call
“Revenues increased 37% to $13 billion driven by strong provider growth, expanded specialty distribution, and contributions from acquisitions completed this fiscal year. Operating profit increased 57% to $366 million led by growth in provider solutions and specialty distribution, including contributions from acquisitions.”
— Britt Vitalone, Chief Financial Officer
“The consistency of this performance gives us the confidence to raise full-year EPS guidance to a range of $38.80 to $39.20, which reflects 17 to 19% year-over-year growth.”
— Brian Tyler, Chief Executive Officer
MCK Q3 FY2026 earnings call transcript · 2026-02-04
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $105.38B | $614M | $5.15 |
| Q1 2026 | $96.30B | $1.68B | $13.71 |
| Q4 2025 | $106.16B | $1.19B | $9.59 |
| Q3 2025 | $103.15B | $1.11B | $8.92 |
Based on FMP financials and quantitative analysis
MCK Latest News
-
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
Zacks · Aug 18, 2026
-
Analyst Report: Cencora, Inc.
Morningstar Research · Aug 12, 2026
-
Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings
MT Newswires · Aug 5, 2026
-
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
zacks.com · Jul 6, 2026
MCK Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCK.
Price Targets
Consensus target: $986.00
MCK MoonshotScore
What does this score mean?
The MoonshotScore rates MCK 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties
Analyst Report: Cencora, Inc.
Stocks Rise Pre-Bell Amid Growing Hopes for Hormuz Deal; Traders Await More Corporate Earnings
Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?
Latest McKesson Corporation Analysis
Leadership: Brian S. Tyler
Chief Executive Officer
Brian S. Tyler has served as the Chief Executive Officer of McKesson Corporation since 2019. Prior to this role, he held various leadership positions within the company, including President and Chief Operating Officer. His extensive experience in healthcare and distribution has been instrumental in shaping McKesson's strategic direction. Tyler's background includes a strong focus on operational efficiency, customer service, and innovation. He is known for his ability to drive growth and improve financial performance.
Track Record: Under Brian Tyler's leadership, McKesson has focused on expanding its technology solutions and strengthening its core distribution business. He has overseen strategic acquisitions and partnerships to enhance the company's market position. Key milestones include the expansion of the RxTS segment and the implementation of advanced supply chain management technologies. Tyler has also emphasized sustainability and corporate social responsibility, aligning McKesson's business practices with broader societal goals.
What Investors Ask About McKesson Corporation (MCK) — Healthcare
What does the AI Score mean for MCK?
MCK holds an AI Score of 90/100 (Grade: A+). This is an educational research signal, not a buy or sell recommendation. McKesson Corporation is a leading healthcare services company, distributing pharmaceuticals and providing healthcare solutions globally. The company operates through four segments: U.S …
What does McKesson Corporation do?
McKesson Corporation is a global healthcare services company that distributes pharmaceuticals and provides medical supplies and technology solutions. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). McKesson connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions. The company's extensive distribution network and comprehensive suite of services make it a critical player in the healthcare ecosystem.
What do analysts say about MCK stock?
Analysts generally view McKesson Corporation as a stable and reliable investment, given its central role in the healthcare supply chain. The consensus rating for MCK stock is typically a 'hold' or 'buy,' with price targets reflecting modest growth potential. Key valuation metrics, such as the P/E ratio and dividend yield, are often considered attractive.
What are the main risks for MCK?
McKesson Corporation faces several key risks, including regulatory changes in the healthcare industry, which could impact pricing and reimbursement. Intense competition from other pharmaceutical distributors and healthcare providers also poses a threat. Cybersecurity threats and data breaches could disrupt operations and damage the company's reputation. Additionally, pricing pressures from payers and government regulations could squeeze profit margins.
What are the key growth opportunities for MCK in healthcare?
McKesson Corporation has several key growth opportunities within the healthcare sector. These include expanding its Prescription Technology Solutions (RxTS) segment to improve medication adherence, making strategic acquisitions in international markets to broaden its geographic reach, and increasing its focus on specialty pharmaceuticals to capitalize on the growing market for innovative therapies.
What revenue streams does McKesson Corporation have in healthcare?
McKesson Corporation generates revenue through several key streams within the healthcare sector. The primary revenue stream is the distribution of pharmaceutical products, including branded, generic, and specialty drugs, to pharmacies and healthcare providers. Additional revenue comes from the distribution of medical-surgical supplies and equipment.
What are the key factors to evaluate for MCK?
McKesson Corporation (MCK) holds an AI score of 90/100 (high). P/E: 19.6x vs the S&P 500's ~20-25x. Analysts target $986.00 (+15%). Not financial advice.
How frequently does MCK data refresh on this page?
MCK's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MCK's recent stock price performance?
McKesson Corporation (MCK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Extensive distribution network and supply chain infrastructure. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on publicly available sources and is intended for informational purposes only. It does not constitute investment advice.